Cutaneous angiosarcoma
Wilson-Jones angiosarcoma (idiopathic scalp); Stewart-Treves syndrome (lymphoedema-associated); post-radiation angiosarcoma
Cutaneous angiosarcoma is an aggressive endothelial-cell sarcoma with a dismal prognosis (median overall survival 12–24 months). Three classical contexts dominate: idiopathic head-and-neck angiosarcoma in elderly white men, post-mastectomy lymphoedema-associated angiosarcoma (Stewart-Treves syndrome), and post-radiotherapy angiosarcoma — most commonly arising in irradiated breast skin years after breast cancer treatment. Bruise-like or "wine-stain" patches are easily mistaken for benign vascular lesions or trauma. The disease is typically multifocal in the surrounding "field"; achieving R0 resection is difficult. Multimodality therapy (wide local excision, radiotherapy, paclitaxel-based chemotherapy) is standard.
Clinical contexts
- Idiopathic (Wilson-Jones) — scalp / facial skin of elderly Caucasian men. Most common type. Median age 70.
- Lymphoedema-associated (Stewart-Treves) — chronic lymphoedema (commonly post-axillary clearance for breast cancer); arms most often. Latency 5–15 years.
- Post-radiation — most often breast skin 5–10 years after adjuvant radiotherapy for breast cancer; can occur in any irradiated field.
- Hereditary / syndromic — rare association with BRCA1/2 (notably post-radiation breast angiosarcoma) and retinoblastoma survivors. NF1 is not a recognised angiosarcoma predisposition — the NF1 sarcoma is malignant peripheral nerve sheath tumour (MPNST). MYC amplification on chr 8q24 is characteristic of radiation-induced and chronic-lymphoedema-associated angiosarcoma.
Clinical features
- Initial presentation often subtle: bruise-like violaceous patches, persistent oedema, or "rosacea-like" facial erythema.
- Progresses to indurated nodules, plaques, ulcers and bleeding.
- Multifocal — visible disease underestimates the true field of involvement; satellite lesions in surrounding apparently normal skin are common.
- Mistaken for benign bruising, port-wine stain, cellulitis, rosacea or radiation dermatitis — index of suspicion required for any persistent unilateral facial discolouration in an elderly patient.
Histology & molecular
- Irregular vascular channels lined by atypical endothelial cells dissecting through dermal collagen.
- Spectrum from well-differentiated (anastomosing channels) to poorly differentiated (epithelioid, spindled).
- CD31, CD34, ERG, FLI-1 and D2-40 (lymphatic) positive.
- MYC amplification (chromosome 8q24) — characteristic of secondary (post-RT, lymphoedema-associated) angiosarcoma; useful to distinguish from atypical vascular lesion (AVL), which is benign and lacks MYC amplification.
Imaging & staging
- MRI of the affected region — defines extent of dermal/subcutaneous infiltration and helps plan resection margins; visible disease typically underestimates true extent.
- CT chest/abdomen/pelvis — staging for distant metastasis (lung most common).
- Multiple mapping biopsies of the surrounding skin to delineate field disease prior to surgery.
Management
- Multidisciplinary (sarcoma MDT, plastic surgery, oncology, radiation oncology) management is essential.
- Wide local excision with the largest feasible margins (often 3–5 cm); free flap or skin-graft reconstruction. R0 resection is often not achievable on the scalp/face.
- Adjuvant radiotherapy to the wide tumour bed reduces local recurrence.
- Systemic chemotherapy — weekly paclitaxel is the most active single agent; doxorubicin alternative. Consider neoadjuvant for borderline-resectable disease.
- Targeted / immunotherapy emerging — pazopanib, propranolol (case-based), checkpoint inhibitors in clinical trials.
- Palliative chemotherapy and electrochemotherapy for unresectable / metastatic disease.
Prognosis
Poor — 5-year overall survival 10–35%. Better outcomes with R0 resection, smaller tumours (<5 cm), absence of multifocality, and trimodality therapy. Local recurrence is the dominant failure pattern; lung is the commonest site of distant metastasis. Follow-up should be sarcoma-MDT led using a high-grade soft-tissue sarcoma approach: clinical review and chest / site-appropriate imaging every 3–6 months for the first 2–3 years, then twice yearly until year 5, then annually; intensify according to grade, extent, margin status and symptoms.
References
- Young RJ et al. Angiosarcoma. Lancet Oncol; 2010.
- Cohen-Hallaleh RB et al. Radiation-induced angiosarcoma of the breast: outcomes from a multidisciplinary unit. Eur J Surg Oncol; 2017.
- Penel N et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma (ANGIOTAX). J Clin Oncol; 2008.
Spot a correction?
If any clinical statement, citation or link on this page needs updating, please email admin@skinoncology.net with the page name, the proposed correction and the supporting source.